Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
2008
2009
2010
Announcements
Articles
Articles and Publications
Campaign
Case Studies
Charge Capture and Pricing
Coding Integrity
Company
Consulting
Craneware Insights Articles
Education
Home
Journey
News & Events
Opportunities
Other
post
Press Releases
Products
Services
Testimonial
Trade Shows
Uncategorized
Uncategorized
Upcoming Events
Value Cycle
Webinars
White Papers

Now that Remdesivir is approved by the FDA, should we be billing this drug with HCPCS code C9399?

On October 22, 2020, the FDA did issue an approval for Remdesivir; this means that the drug does meet the HCPCS definition of code C9399. However, it is important to point out that the FDA approval still reserves the use of Remdesivir for only those patients requiring inpatient hospital care. With the exception of hemophilia clotting factors, neither revenue code 636 or drug HCPCS codes are reported on inpatient claims.  From a chargemaster perspective, it is likely not necessary to assign HCPCS C9399 to your charges for Remdesivir as this HCPCS code will not be reported on your corresponding inpatient claims.

FDA Approval Notification for Remdesivir:
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19